Julia Rotow MD

Clinical Director, Lowe Center for Thoracic Oncology @DanaFarber
Assistant Professor, Harvard Medical School #NSCLC #EGFR

[Julia Rotow MD @JuliaRotow]

Join us on November 2nd for the annual DFCI EGFR Center Patient and Caregiver Forum, details and register below!

[Dana-Farber's EGFR Mutant Lung Cancer Center @DFEGFRcenter]

REGISTER NOW for the Chen-Huang Center's 6th Annual Patient & Caregiver Forum on Monday, Nov 2, 2026 from 6-8pm ET. This event is virtual, open to the public, and FREE: https://t.co/PS9Up4musR
E-mail [email protected] with any questions! #lungcancer #EGFR #NSCLC #LCAM

[Julia Rotow MD @JuliaRotow]

@sands_jacob @IDEOlogyHealth Will be important to establish time to wash out of ivonescimab to help gauge risk with subserquent next line TKI containing regimens

[Julia Rotow MD @JuliaRotow]

@IDEOlogyHealth MET IHC may be a useful tie-breaker here as well

[Julia Rotow MD @JuliaRotow]

@IDEOlogyHealth Ordered after NGS on newly diagnosed adenocarcinoma. At PD on TKIs as well.

[Julia Rotow MD @JuliaRotow]

The DFCI EGFR Center’s annual patient and caregiver forum is next month. Register to attend through the link below - we hope you can join us!

[Dana-Farber's EGFR Mutant Lung Cancer Center @DFEGFRcenter]

REGISTER NOW for the Chen-Huang Center's Fifth Annual Patient & Caregiver Forum, which will take place on Monday, November 17, 2025 from 6-8pm ET on Zoom and is FREE: https://t.co/AoSCe8sCUU
E-mail [email protected] with any questions!
#lungcancer #EGFR #LCAM
#FlorezLab

[IDEOlogy Health @IDEOlogyHealth]

IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab + chemo outperformed tislelizumab + chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?

[IDEOlogy Health @IDEOlogyHealth]

IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?

[IDEOlogy Health @IDEOlogyHealth]

IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?

[Julia Rotow MD @JuliaRotow]

Join me on August 18 & 19 to hear inspiring stories from Dana-Farber patients and donate to strike out cancer: https://t.co/sJZT3wts2m #KCANCER @TheJimmyFund

Sharing progress in personalized treatment for #lungcancer @DFarberThoracic @DFEGFRcenter

[Julia Rotow MD @JuliaRotow]

@ACortelliniMD Looking forward to a great discussion with real world clinical impact. Join us tomorrow morning to debate: what is the right call in 1L EGFRm NSCLC #ASCO25 #EGFR @ACortelliniMD #JessicaBauman

[Julia Rotow MD @JuliaRotow]

Follow us at the DFCI EGFR Center for updates on emerging data from #ASCO25
@DFEGFRcenter #NSCLC #EGFR
OptiTROP-Lung03: sac-TMT
NeoADAURA: neoadj osi/chemo
HERTHENA-Lung02: HER3-DXd vs doublet
Temab-A MET ADC
SACHI: osi/savolitinib MET+
Zipalertinib and BAY2927088 EGFR ex20ins+

[Julia Rotow MD @JuliaRotow]

#ASCO25 is here! Join me Monday at 8:30 AM at the Arie Crown Theater to explore the role of plasma-guided adaptive first-line chemoimmunotherapy for NSCLC, abstract #8515 https://t.co/V2c9mYJakF

[Julia Rotow MD @JuliaRotow]

I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: https://t.co/wJP6tC0u1V #LCSM #NSCLC

[Julia Rotow MD @JuliaRotow]

Kicking off #TTLC22 with a discussion of EGFR-mutant NSCLC. Great to see and discuss all the advances in the last year.

[Julia Rotow MD @JuliaRotow]

A9 We are on the way to making #lungcancer a chronic disease - seeing gains in long-term survivability and more advances to come #AskReuters #ASCO2021

[Julia Rotow MD @JuliaRotow]

A8 @DeboraBruno (abstract 9005 #ASCO21) describes lower rates of NGS testing and clinical trial enrollment among African American versus Caucasian patients, highlighting reduced access to many of the advances that we celebrate at the annual meeting #AskReuters

[Julia Rotow MD @JuliaRotow]

A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021

[Julia Rotow MD @JuliaRotow]

A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters

[Julia Rotow MD @JuliaRotow]

Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021

[Jyoti D Patel @JPatelMD]

#AskReuters#ASCO2021 We underutilize CT screening. Only 1 in 8 Americans who are eligible, get potentially life saving screening.

[Julia Rotow MD @JuliaRotow]

Q3 We see the stigma in society’s attitudes towards this diagnosis and in a paucity of public and private funding compared to other common cancer diagnoses. Though lung cancer is the #1 cause of cancer mortality, funding lags that of other diseases #AskReuters

[Julia Rotow MD @JuliaRotow]

Q3 We need to bring visibility to the ‘invisible disease’ through awareness and funding campaigns. It is also important to note that up to 50% of lung cancer occurs in those who have already quit smoking and in young patients >25% will be never smokers #AskReuters #ASCO21